TWD 70.6
(3.22%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 78.39 Million TWD | 106.47% |
2022 | 37.97 Million TWD | 42.62% |
2021 | 26.62 Million TWD | 108.96% |
2020 | 12.74 Million TWD | 87.29% |
2019 | 6.8 Million TWD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 22.17 Million TWD | 333.29% |
2024 Q2 | 16.8 Million TWD | -24.23% |
2023 Q4 | 5.11 Million TWD | -72.55% |
2023 FY | 78.39 Million TWD | 106.47% |
2023 Q3 | 18.64 Million TWD | -40.76% |
2023 Q2 | 31.47 Million TWD | 35.93% |
2023 Q1 | 23.15 Million TWD | 121.27% |
2022 FY | 37.97 Million TWD | 42.62% |
2022 Q4 | 10.46 Million TWD | 0.0% |
2021 FY | 26.62 Million TWD | 108.96% |
2020 FY | 12.74 Million TWD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
DIVA Laboratories, Ltd. | 73.61 Million TWD | -6.496% |
Genetics Generation Advancement Corp. | 28.56 Million TWD | -174.458% |
Welgene Biotech Co.,Ltd. | -2.64 Million TWD | 3060.687% |
Puriblood Medical Co., Ltd. | -51.59 Million TWD | 251.951% |
TFBS Bioscience Inc. | 4.9 Million TWD | -1497.046% |